- Home
- HCA vs SNY Comparison
HCA vs SNY Comparison
Compare HCA & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCA | SNY |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0B | 119.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HCA | SNY |
|---|---|---|
| Price | $500.74 | $47.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 6 |
| Target Price | ★ $510.21 | $61.50 |
| AVG Volume (30 Days) | 1.2M | ★ 3.9M |
| Earning Date | 01-27-2026 | 01-29-2026 |
| Dividend Yield | 0.62% | ★ 3.34% |
| EPS Growth | 28.76 | ★ 44.16 |
| EPS | ★ 28.33 | 7.52 |
| Revenue | ★ $75,600,000,000.00 | $54,850,299,422.00 |
| Revenue This Year | $5.10 | $2.70 |
| Revenue Next Year | $4.90 | $6.84 |
| P/E Ratio | $17.71 | ★ $12.51 |
| Revenue Growth | ★ 7.08 | 5.49 |
| 52 Week Low | $295.00 | $44.62 |
| 52 Week High | $527.56 | $60.12 |
Technical Indicators
Market Signals| Indicator | HCA | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 64.98 | 49.62 |
| Support Level | $492.96 | $47.20 |
| Resistance Level | $517.67 | $48.60 |
| Average True Range (ATR) | 12.04 | 0.70 |
| MACD | 3.82 | 0.16 |
| Stochastic Oscillator | 81.61 | 65.52 |
Price Performance
Historical ComparisonAbout HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.